Biomarker Assay Identifies DCIS Patients at Increased Risk for Breast Cancer-Specific Death

Higher DCISionRT scores in patients with ductal carcinoma in situ (DCIS) identify an increased risk of breast cancer-specific mortality (BCM), according to data presented at the Miami Breast Cancer Conference (MBCC) 2021 Annual Meeting by Laguna Hills, Calif-based PreludeDx.¹

The study—“A biomarker assay predicts women diagnosed with DCIS without microinvasion at increased risk for breast cancer specific death”—included 414 women in the original case control study (96 women who died of breast cancer and 318 controls from a population of 6,964 in Sweden diagnosed with DCIS without microinvasion). A prior nested case control study was used due to the low incidence of death in DCIS.

“In our study, treatment was not independently associated with decreased BCM risk. In fact, the women selected for treatment with mastectomy tended to have increased BCM compared to those who were treated with BCS,” says Charlotta Wadsten, MD, PhD, of Umea University. “The study demonstrated that the DCISionRT Decision Score was significantly associated with breast cancer mortality, while clinicopathologic factors were not.”

The primary endpoint of the study was to identify the association of DCISionRT test results with breast cancer mortality. DCISionRT Decision Score (DS) results were available for 157 of the 414 women. Primary DCIS was treated with breast conserving surgery (BCS) alone, BCS plus radiotherapy or mastectomy in 34%, 29%, and 37% of the cases, respectively. Results revealed patients with increasing continuous DS had increasing BCM (OR=10, p=0.004), and patients with high categorical DS (>6) were at greater risk of BCM (OR=19, p=0.007).

“The more information that we can provide the physician and patient, the more confidence they will have in making a treatment recommendations and decision,” says Dan Forche, President and CEO of PreludeDx. “This data demonstrates that  DCISionRT may help to identify patients at greater risk for breast cancer mortality and provide the information for physicians to implement more aggressive upfront treatment when needed.”

For more information, visit PreludeDx.

Reference

1. Wadsten C, Rabinovitch R, Vicini F, et al. “A biomarker assay predicts women diagnosed with DCIS without microinvasion at increased risk for breast cancer specific death.” Poster presentation at the Miami Breast Cancer Conference (MBCC) 2021 Annual Meeting. Available at: https://preludedx.com/wp-content/uploads/2021/03/2021-MBCC-Poster-1_DCISionRT-and-BCM_v21-Read-Only.pdf. Accessed March 15, 2021.